The stock of Roivant Sciences Ltd (NASDAQ:ROIV) last traded at $8.72, up 1.45% from the previous session.
Data from the available sources indicates that Roivant Sciences Ltd (NASDAQ:ROIV) is covered by 10 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $12.00, we find $16.00. Given the previous closing price of $8.60, this indicates a potential upside of 86.05 percent. ROIV stock price is now -20.36% away from the 50-day moving average and -8.99% away from the 200-day moving average. The market capitalization of the company currently stands at $6.90B.
In total, 1 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $16.44 as their price target over the next twelve months.
With the price target of $17, Guggenheim recently initiated with Buy rating for Roivant Sciences Ltd (NASDAQ: ROIV).
In other news, Venker Eric, Chief Operating Officer sold 153,027 shares of the company’s stock on Oct 05. The stock was sold for $1,547,103 at an average price of $10.11. Upon completion of the transaction, the Chief Operating Officer now directly owns 595,397 shares in the company, valued at $5.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03, Chief Operating Officer Venker Eric sold 606,221 shares of the business’s stock. A total of $6,213,765 was realized by selling the stock at an average price of $10.25. This leaves the insider owning 595,397 shares of the company worth $5.19 million. A total of 32.61% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ROIV stock. A new stake in Roivant Sciences Ltd shares was purchased by AVORO CAPITAL ADVISORS LLC during the first quarter worth $50,630,000. FARALLON CAPITAL MANAGEMENT LLC invested $20,536,000 in shares of ROIV during the first quarter. In the first quarter, LOOMIS SAYLES & CO L P acquired a new stake in Roivant Sciences Ltd valued at approximately $17,096,000. AVIDITY PARTNERS MANAGEMENT LP acquired a new stake in ROIV for approximately $14,715,000. DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC purchased a new stake in ROIV valued at around $12,729,000 in the second quarter. In total, there are 211 active investors with 49.01% ownership of the company’s stock.
During the past 12 months, Roivant Sciences Ltd has had a low of $4.10 and a high of $13.24. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 6.37, and a quick ratio of 6.35. The fifty day moving average price for ROIV is $10.89 and a two-hundred day moving average price translates $9.58 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.3 by -0.08. This compares to -$0.51 EPS in the same period last year. The net profit margin was -1233.11% and return on equity was -94.44% for ROIV. The company reported revenue of $21.62 million for the quarter, compared to $4.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 400.67 percent. For the current quarter, analysts expect ROIV to generate $30.12M in revenue.
